We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

JEOL

JEOL is a leading global supplier of electron microscopes, ion beam instruments, mass spectrometers and NMR spectrome... read more Featured Products: More products

Download Mobile App





JEOL Ltd. Introduces BioMajesty Series of Clinical Chemistry Analyzers at MEDICA 2019

By LabMedica International staff writers
Posted on 18 Nov 2019
JEOL Ltd. More...
(Tokyo, Japan) introduced its BioMajesty series of clinical chemistry analyzers featuring unique but proven technologies at this year's MEDICA, the world's largest annual medical technology trade fair, which took place from 18-21 November in Düsseldorf, Germany. At the 2019 edition of MEDICA, more than 5,000 exhibitors from 70 countries presented their newest products and ideas. The event also drew more than 120,000 trade visitors from over 170 countries.

JEOL offers the BioMajesty series of clinical chemistry analyzers which use micro volume of samples and reagents to deliver highly-accurate, high-speed processing through the incorporation of a sample dilution tray, which is an outstanding unique feature of all BioMajesty analyzers.

At the 2019 edition of MEDICA, JEOL showcased its BioMajesty series of clinical chemistry analyzers, which include the JCA-ZS050, JCA-BM6070/C and JCA-BM6010/C. The JCA-ZS050 clinical chemistry analyzer is bolstered by the breakthrough technology and unique dilution mechanism of the series. The JCA-ZS050 boasts of extra-micro-volume measurement with minimum 40μL reaction volume. The 1,800 throughput/hour next-generation chemistry analyzer from JEOL brings innovative operation and simple maintenance, while assuring high-precision data empowered by its novel wash mechanism.

The JCA-BM6070/C clinical chemistry analyzer has 2,400 tests/hour throughput, achieving unprecedented ultrafast processing capability in the 2.0-second cycle time. While realizing minimum reaction volume of 60μl by its unique pre-dilution mechanism, it offers high data reliability and excellent cost benefits.

The JCA-BM6010/C is a compact, reliable chemistry system with versatile functions, offering a maximum throughput of 800 tests/hour for photometry and 1,200 tests/hour with ISE. Bolstered by unique micro-volume technology, a strong tradition of BioMajesty series, it streamlines the daily laboratory routine by automatic on-board hemolysis for HbA1c. The JCA-BM6010/C’s0 superior usability with STAT port and Smart Pause/Smart Start features in its optimized space-saving design help deliver more flexibility.

Related Links:
JEOL Ltd.


New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.